Dilemmas in treating smoldering multiple myeloma
Inhye E Ahn1, Sham Mailankody1, Neha Korde1
1Inhye Ahn and Sham Mailankody, the National Cancer Institute, National Institutes of Health, Bethesda, MD; Neha Korde and Ola Landgren, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract:
Novel therapies hold promise for high-risk smoldering multiple myeloma (SMM). Recent studies suggest that modern combination approaches can be options for high-risk SMM to obtain deep molecular responses with favorable toxicity profiles. Although pioneering treatment trials based on small numbers of patients suggest progression-free and overall survival benefits, application of the data to real-life practice remains to be validated. Therapeutic modulation of disease tempo, disease burden, clonal evolution, and tumor microenvironment in SMM remains to be understood and calls for reliable biomarkers reflective of disease biology. Here, we review studies that open a new management platform for SMM, address ongoing dilemmas in practice and under investigation, and highlight emerging scientific questions in the era of SMM treatment.
Insights
Novel therapies offer hope for high-risk smoldering multiple myeloma (SMM). Research indicates combination treatments may improve outcomes, but real-world validation and understanding of disease biology are needed.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- High-risk smoldering multiple myeloma (SMM) presents a therapeutic challenge.
- Emerging novel therapies and combination approaches show potential for deep molecular responses in SMM.
- Current treatment benefits require validation in real-world clinical practice.
Purpose of the Study:
- To review recent advancements in novel therapies for high-risk smoldering multiple myeloma.
- To address current clinical dilemmas and ongoing investigations in SMM management.
- To highlight key scientific questions regarding SMM biology and treatment.
Main Methods:
- Review of recent scientific literature and clinical trial data on SMM therapies.
- Analysis of studies focusing on combination approaches and their outcomes.
- Discussion of biomarkers and disease modulation in the context of SMM.
Main Results:
- Novel combination therapies show promise for high-risk SMM with favorable toxicity.
- Early trials suggest potential progression-free and overall survival benefits.
- The application of these findings to routine clinical practice needs further validation.
Conclusions:
- Modern combination treatments represent a new management platform for high-risk SMM.
- Further research is essential to understand disease biology, identify biomarkers, and validate therapeutic strategies.
- Addressing clinical dilemmas and unanswered questions is crucial for optimizing SMM care.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistent Cancers
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...